重组人脑利钠肽滴定给药方法治疗难治性急性失代偿心力衰竭的效果与安全性

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy and safety of Recombinant Human Brain Natriuretic Peptide(rhBNP)titration in the treatment of refractory acute decompensated heart failure(ADHF).Methods A total of 300 patients with refractory ADHF admitted to the Ansteel Group General Hospital from June 2018 to June 2020 were selected as the research objects.They were divided into the group A(150 cases)and the group B(150 cases)according to the random odd and even number method.The group A was given rhBNP fixed dose administration scheme,and the group B was given rhBNP titration dose administration scheme.The 24 hours urine volume,systolic blood pressure(SBP),mean arterial pressure(MAP),N-terminal pro brain natriuretic peptide(NT-proBNP),aldosterone(ALD),creatinine clearance rate(CC),left ventricular ejection fraction(LVEF),pulmonary artery pressure(PAP),hospitalization time,thirty days readmission rate and adverse reactions were compared between the two groups.Results Before the treatment,there were no significant differences in 24 hours urine volume,SBP,MAP,NT-proBNP,ALD,CC,LVEF and PAP between the two groups(P>0.05).After the treatment,24 hours urine volume of the group B was higher than that of the group A,SBP,MAP,NT-proBNP,ALD,PAP values of the group B were lower than those of the group A,the differences were statistically significant(P<0.05).There were no significant differences in CC and LVEF between the two groups(P>0.05).The hospitalization time of the group B was shorter than that of the group A,thirty days readmission rate of the group B was lower than that of the group A,and the differences were statistically significant(P<0.05).There was no significant difference in total incidence of adverse reactions between the two groups(P>0.05).Conclusion Giving rhBNP titration to treat the patients with refractory ADHF,the effect of symptom relief is better,and the safety of clinical treatment is also considered.

Key words： Recombinant Human Brain Natriuretic Peptide Titration administration Refractory Acute decompensation Heart failure

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JING Feng

Cite this article:

JING Feng. Effect and safety of titrated Recombinant Human Brain Natriuretic Peptide in the treatment of refractory acute decompensated heart failure[J]. 中国当代医药, 2021, 28(22): 24-27.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I22/24

[1]	周立涛，向常清.CRRT 联合重组人脑利钠肽对CRS 难治性心力衰竭患者NT-ProBNP、心肾功能的影响[J].中国医院药学杂志，2020，40（8）：937-940.
[2]	贾文侠，祁丽蓉.重组人脑利钠肽联合托伐普坦治疗老年慢性心力衰竭合并利尿剂抵抗患者的临床研究[J].中国临床药理学杂志，2020，36（18）：2748-2751.
[3]	崔建国，梁淑芹，齐洁，等.小剂量联合重组人脑利钠肽和沙库巴曲缬沙坦治疗老年急性心力衰竭的短期疗效[J].实用医学杂志，2020，36（21）：2984-2989.
[4]	陈功，杨方，魏刚，等.重组人脑利钠肽联合左西孟旦治疗急性失代偿性心力衰竭合并肾功能不全的临床观察[J].中国药房，2020，31（21）：2639-2644.
[5]	冯雪，吴岳，孟颖，等.重组人脑利钠肽对重症心力衰竭患者的疗效和安全性：一项前瞻性多中心临床研究[J].中华危重病急救医学，2017，29（6）：520-524.
[6]	冯婧，鲁佳佳，赵琳.重组人脑利钠肽联合左西孟旦对老年急性失代偿性心力衰竭患者心功能和血清N 末端B型脑钠肽前体及和肽素水平的影响[J].中国医药，2020，15（5）：665-668.
[7]	李爱霞，罗国帅，曲鹏展，等.重组人脑利钠肽治疗慢性心力衰竭的临床疗效及对白细胞介素-23、N-末端脑钠肽前体的影响[J].中西医结合心脑血管病杂志，2019，17（24）：3988-3991.
[8]	章明，张健，郝淑新，等.重组人脑利钠肽应用于高龄患者心力衰竭的疗效及安全性[J].武警医学，2019，30（9）：745-748，751.
[9]	陈根，钱福东，冯俊，等.重组人脑利钠肽联合多巴酚丁胺治疗慢性肺源性心脏病心力衰竭的临床研究[J].中国临床医生杂志，2020，48（8）：921-923.
[10]	吴琼，陈还珍，盖婉丽.重组人脑利钠肽治疗急性心肌梗死合并心力衰竭的效果[J].中国心血管杂志，2019，24（3）：250-253.
[11]	熊三军，马江伟，乔增勇.重组人脑利钠肽治疗心力衰竭临床效果及对患者尿量、心功能、炎症指标的影响[J].陕西医学杂志，2019，48（1）：99-101.
[12]	查慰，王戈，谢婷，等.重组人脑利钠肽对重症心肌炎合并急性心力衰竭患者的疗效及炎症因子的影响[J].武汉大学学报（医学版），2019，40（4）：645-649.
[13]	李娜丽，陈亚军，王怀祯，等.重组人脑利钠肽治疗老年急性失代偿心力衰竭的临床研究[J].中国临床药理学杂志，2019，35（8）：734-736.
[14]	李娜，盛柯杰，白梦蝶，等.重组人脑利钠肽治疗急性心力衰竭的疗效及对血清炎性因子的影响[J].海军医学杂志，2019，40（4）：333-335.
[15]	符孝磊，张慧.重组人脑利钠肽可有效治疗慢性心力衰竭急性失代偿性重症[J].基因组学与应用生物学，2019，38（8）：3786-3790.
[16]	黄山见，余宏斌，朱洪斌，等.重组人脑利钠肽治疗急性失代偿性心力衰竭的疗效观察[J].中西医结合心脑血管病杂志，2020，18（5）：811-814.
[17]	徐烨，王海峰.不同剂量重组人脑利钠肽治疗急性失代偿性心力衰竭合并肾功能不全的疗效及安全性比较[J].中国医师进修杂志，2020，43（12）：1114-1119.
[18]	安乐，隋春兴，王力，等.重组人脑利钠肽不同给药方式治疗急性失代偿心力衰竭的临床效果比较[J].中华老年多器官疾病杂志，2020，19（10）：769-772.
[19]	蔡香香.重组人脑利钠肽对老年慢性心衰急性加重期患者心功能及BNP 水平的影响[J].当代医学，2021，27（2）：139-140.
[20]	方文宾，王文标，潘一先，等.重组人脑利钠肽对急性冠脉综合征伴心力衰竭患者的影响[J].中国现代医生，2020，58（25）：42-45.
[21]	刘友萍，荣惠，沈相福.静脉应用重组人脑利钠肽治疗急性失代偿性心力衰竭患者的临床疗效及对心功能的影响[J].中国现代医生，2019，57（18）：46-48.